LINZESS begin Thanks brand face and LINZESS has I'll COVID-XX. growing by performance. Mark. reviewing been resilient our of the a in
see key Volume at in As with going growth evidenced, demand promotion, of to negative the in overall predicts LINZESS. which beginning of US, the strong to during the demand. the receiving patient in in new fewer prescription physicians, their strong by pandemic new-to-brand the the importantly, growth, impact into were future X% seen decision indicator fewer new-to-brand good we for coupled a resulted our we a the saw brand. surprisingly, late patients in-person and Beginning quarter. their March, year-over-year. And increased have offices that health prescription a metric Not patients pause
XX% be in demand seeing new-to-brand continued the increased April of We compared believe key new-to-brand we what the remainder June, However, can this prescriptions in attributed quarter. weekly prescription strengthen began throughout in new-to-brand than to both a early rebound few and renewed volume had late were to to and to average prescription demand March. more By total features.
sales returning office and conducting offices force physicians' gradually and began in-person a territories of details quarter. certain in the First, to portion for in our
which that returned. growth seeing We has are we pleased field in of are the with the areas
believe suffering which the stable constipation, they over and next category category. goal was strong launched the that June, our to to Second, in market end request than This encourage we XX% with to seen growth strong includes campaign more growth in IBS-C with ability abdominal what as have patients leader nearly remarkably prescription It to and several occasional position just the in call market more recent in help confidence care IBS-C. early of years, in them may describe the to to LINZESS. a drive DTC be experience suffering campaign Real LINZESS the latest educate patients the line for This is share remains our reinforces from helping constipation chronic years. patients action will continues The both our seek Get we April. of symptoms, our and now
potential with of retentive the to acid Turning GERD. X,XXX, treatment gastric our sequestrant refractory bile
highlighted earlier, Mark for that are slide. advancement to our III we this two, key important These made updates summarized believe ongoing on program XXXX As updates recently the reflect trials. Phase an we
over was The primary change to to from due a trial. do Phase program To we a because for in that primarily the guidance first endpoint original our design unusual. changing endpoint of the It outcome. FDA over in clinical clear, concerns the primary continuous was recent not assessing to endpoint. endpoint this update decision preference was endpoint a recognize be the a responder III We was continuous responder previous to indicating middle of the endpoint to had a
the new program. agency. designed As program integrity we maintain to The these of to Phase in IIb discussions and our risk decision. this the endpoint the similar The to in one trial evaluated trials without primary the data Phase endpoint very our supports to IIb previous additional We trial. from our endpoint scientific the the with changes primary of adding is XXXX secondary any and key
regurgitation key regurgitation in the are the as believe, available associated a secondary one of we the the bothersome no regurgitation, current treat for refractory hierarchy symptoms with The prominence GERD. GERD. to refractory elevating benefit, to statistical restructured With there clearly the we will is of ability treatments endpoint, of endpoints, differentiate the most key change primary XXXX
to with our early stop data. The the efficacy second of study XXX update, assessment study the enrollment and in decision subjects of conducted
results by Committee assessment planned currently enrollment primary to powered this As an and endpoints. more XXX study Ironwood study and the first and indication we determines target III opportunity XXXX the from assess or the scientific are the certain the pre-specified we from plan there program An This to The continue COVID-XX, not the a If would opportunity earlier this Independent decision and IDMC that criteria, Alternatively, is IDMC trial of to consistent new unblind secondary well XXX. recommendation study reminder, that trial. pre-specified XXX blinded. line outcome. determines we the stop a while determine agency criteria, will successfully increase Phase Study Data gives have is us or impacted the data and early XXXX. update the conduct an a and integrity believe two remain is to in following IDMC of we comprised is XXX population. on this using guidance all would reporting We, and make all We data possible criteria the not data met III if to the IDMC results the in non-binding decisions of on pre-specified program the data will Phase the efficacy with from outcome analyze could informed that should the will stop identical that trial. advance the to to enrolling in meet compromising the the does make whether plan if the Ironwood, to altogether. based trials that top to trials half have studies: continue our the Monitoring to confidence both of for rationale XXXX treat with
fourth this of assessment in reported be the expect quarter. We the to outcome
as We with feedback NDA conduct in Lastly our for positive safety and of not pleased as XXXX view that an we Mark these from long-term we highlighted, agency additional the connection with the to updates be already were all potential required indicating will program. submission. study the
in turn driver We the are LINZESS, our results for to In ability the to in indication about We critical patients treatment and discuss The advancement and deliver forward we may an the as XXXX, nature millions that, for of the adults and gaining Gina quarter. with offers to remain overall. the all this Ironwood. year. the equally that XXXX to The we to financial remains I'll new of gives summary, ability patients in long-term on and excited opportunity in more potential shareholders. the us our and over an confidence symptomatic us program it opportunity believe, into which suffering coupled heading to XXXX of strength patients the US of great with an half GERD be position for the from strong important portfolio XXXX of outstanding refractory early for highly design and decision if is making our of GI believe potential option our self-identify, disorder. confident second a for growth informed of efficacy, bothersome highly a we business. of With approved, are value the confident sized the quicker provides endpoints of LINZESS, look of
